Navigation Links
Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial,Targeting System's Success in Mouse Model Reported in Cancer Cell

eriments showed gene activity was limited to pancreatic cancer cells and was minimal or absent from other cancers and three lines of normal pancreatic, lung and breast cells.

The next step was to load the vector with a weapon. The team packaged its mutant version of the Bik gene along with C-VISA in a liposome. For comparison, the liposomal gene also was attached to the CMV vector.

They tested both systems in the lab against all 13 available human cell lines of pancreatic cancer available worldwide. BikDD killed cells in all lines, with the VISA-delivered gene destroying more cells in all but one case. The C-VISA system spared healthy tissue while CMV-BikDD destroyed healthy cells. Subsequent tests compared the two methods in the mouse models.

Hung's team continues research on gene expression vehicle. "VISA is versatile enough that if you change the promoter, you could target other cancers or even other diseases," Hung says.

Research was funded by Abbruzzese's pancreatic cancer SPORE grant from the NCI, M. D. Anderson's NCI center support grant, a grant from the Topfer Research Funds, and an AstraZeneca Fellowship.

M. D. Anderson has filed for a patent on VISA-BikDD, which has been licensed to Alchemgen Therapeutics Inc. (ATI). ATI partially supports Hung's research. Hung and M. D. Anderson own stock in the company. These arrangements are managed by M. D. Anderson in accordance with its conflict of interest policies.

Co-authors of the Cancer Cell paper with Hung, Abbruzzese and Xie are: Weiya Xia, Hsu-Ping Kuo, Yuanfang Liu, Zheng Li, Qingqing Ding, Su Zhang, Bill Spohn, Yan Yang, Yongkun Wei, and Jing-Yu Lang, all of the Department of Molecular and Cellular Oncology; and Zhongkui Li, Douglas B. Evans, and Paul J. Chiao, all of the Department of Surgical Oncology. Kuo and Hung also are affiliated with the Graduate School of Biomedical Sciences, operated jointly by M. D. Anderson and The University of Texas Health Science Cen
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
5. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
6. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
7. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
8. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
9. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
Post Your Comments:
(Date:11/1/2014)... companies EBI, LLC, of New Jersey , and ... pay the United States $6.07 million to ... the companies, bone growth stimulators. The settlement this week ... Biomet, Yue Yu, pursuant to the qui tam provisions ... , LLP, a Philadelphia -based personal injury law ...
(Date:11/1/2014)... Wash. , Oct. 31, 2014 Talyst, ... at the 2014 American Society of Consultant Pharmacists (ASCP) ... The meeting and expo will bring together pharmacists and ... the latest technologies. In recent years, ... focus for LTC pharmacies. The InSite® System, Talyst,s LTC ...
(Date:11/1/2014)... and CHICAGO , Oct. 31, 2014 ... Durata Therapeutics, Inc. (NASDAQ: DRTX ) today ... granted early termination of the waiting period under the ... to Actavis, pending acquisition of Durata. Logo ... termination of the HSR waiting period satisfies one of ...
Breaking Medicine Technology:Biomet to Pay Over $6 Million to Resolve Whistleblower Claims That It Paid Kickbacks to Doctors 2Talyst Exhibits at ASCP Annual Meeting 2Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 2Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 3Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 4Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 5Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 6
... 2011 As part of a nationwide effort to prevent ... supporting National Prescription Drug Take-Back Day, which is ... on Saturday, October 29. "Unused prescription medicines that ... are not handled properly," said Paul Kaplan, M.D., BCBSD Vice ...
... information from a recent proprietary study affirming that seeing is ... seeing was an overwhelming choice, selected by 10 times as ... "This research affirms how important seeing is to people and ... VisionSpring President. "With over 700 million people in the world ...
Cached Medicine Technology:Blue Cross Blue Shield of Delaware Supports the Drug Enforcement Administration's "National Prescription Drug Take-Back Day" 2VisionSpring Research Finds Seeing to be the Most Important of Five Senses 2
(Date:10/31/2014)... (PRWEB) October 31, 2014 Springboard ... for its small scale BioPro™ biodiesel processors, announced ... will further improve the performance and efficiency of ... GL95/MC12/BD380 trio will recover more than ... in with the glycerin by-product produced while making ...
(Date:10/31/2014)... October 31, 2014 The Memory Healer review ... by Alexander Lynch, whose father suffered from Alzheimer's disease. ... moment, caused by his father's disease. His father pointed a ... the crucial moment when the author of this method understood ... , The Memory Healer program is based on years ...
(Date:10/31/2014)... October 31, 2014 At the start ... families narrowly escaping carbon monoxide poisoning in their homes. ... weeks away, one family-owned, Missouri-based heating and cooling company ... making sure families start the home heating season with ... secure. , Beginning Nov. 1, 2014, E and ...
(Date:10/31/2014)... Surgery for low back pain caused by spinal stenosis ... live, a new report says. "Nearly 80 percent ... point in their lives, and about 30 million people ... problem," co-author Brook Martin, of the Dartmouth Institute of ... news release. In spinal stenosis, thickening of tissue ...
(Date:10/31/2014)... research suggests that insomnia is a major contributor to ... fatal injuries. The results underscore the importance of the ... Sleep Awareness Project. , Results show that the risk ... with the number of insomnia symptoms present. People with ... likely to die from a fatal injury than those ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
... , ... ... , , , , ... ...
... A surge in volunteers following a major ... coordination, can actually make a situation worse instead of ... the devastating earthquake that rocked Haiti in January provides ... say the authors of a New England Journal ...
... ... in Direct Selling Industry With the Promotion of the First EcoAdvisor to Achieve EcoDirector ... ... one of its founding EcoAdvisors has reached the highest level of achievement, EcoDirector status. ...
... ... unrecognized set of targets and biomarkers to battle solid tumors. , ... (Vocus) February 24, 2010 -- Cancer researchers ... battle solid tumors. , , , , ,The findings center on discovery of signaling ...
... ... ... ... ...
... , ... ... ... ...
Cached Medicine News:Health News:Pelosi on Repealing Antitrust Exemption: Health Insurance Companies Will Now Be Playing on the People's Field 2Health News:Pelosi on Repealing Antitrust Exemption: Health Insurance Companies Will Now Be Playing on the People's Field 3Health News:Pelosi on Repealing Antitrust Exemption: Health Insurance Companies Will Now Be Playing on the People's Field 4Health News:Pelosi on Repealing Antitrust Exemption: Health Insurance Companies Will Now Be Playing on the People's Field 5Health News:Health care volunteers and disasters: First, be prepared 2Health News:OnlyGreen Celebrates First EcoDirector 2Health News:New Cancer-Fighting Strategy Focuses On Signaling Molecules 2Health News:New Cancer-Fighting Strategy Focuses On Signaling Molecules 3Health News:U.S. Senate Urgently Needs to Extend 'Medicaid Match' in Economic Recovery Legislation 2Health News:U.S. Senate Urgently Needs to Extend 'Medicaid Match' in Economic Recovery Legislation 3Health News:U.S. Senate Urgently Needs to Extend 'Medicaid Match' in Economic Recovery Legislation 4Health News:U.S. Senate Urgently Needs to Extend 'Medicaid Match' in Economic Recovery Legislation 5Health News:Express Scripts Reports Strong Fourth Quarter Earnings 2Health News:Express Scripts Reports Strong Fourth Quarter Earnings 3Health News:Express Scripts Reports Strong Fourth Quarter Earnings 4Health News:Express Scripts Reports Strong Fourth Quarter Earnings 5Health News:Express Scripts Reports Strong Fourth Quarter Earnings 6Health News:Express Scripts Reports Strong Fourth Quarter Earnings 7Health News:Express Scripts Reports Strong Fourth Quarter Earnings 8Health News:Express Scripts Reports Strong Fourth Quarter Earnings 9Health News:Express Scripts Reports Strong Fourth Quarter Earnings 10Health News:Express Scripts Reports Strong Fourth Quarter Earnings 11Health News:Express Scripts Reports Strong Fourth Quarter Earnings 12Health News:Express Scripts Reports Strong Fourth Quarter Earnings 13Health News:Express Scripts Reports Strong Fourth Quarter Earnings 14Health News:Express Scripts Reports Strong Fourth Quarter Earnings 15Health News:Express Scripts Reports Strong Fourth Quarter Earnings 16Health News:Express Scripts Reports Strong Fourth Quarter Earnings 17Health News:Express Scripts Reports Strong Fourth Quarter Earnings 18Health News:Express Scripts Reports Strong Fourth Quarter Earnings 19Health News:Express Scripts Reports Strong Fourth Quarter Earnings 20Health News:Express Scripts Reports Strong Fourth Quarter Earnings 21Health News:Express Scripts Reports Strong Fourth Quarter Earnings 22
Acuvue Toric is an exceptionally comfortable soft contact lens made especially for people with astigmatism. The Acuvue Toric lens is designed to comfortably fit the unique shape of your eye....
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
... Vitrasert implant is a device that ... Aids-related Cytomegalovirus (CMV) Retinitis. This approach ... when compared with conventional intravenous treatment. ... in a polymer-based system that slowly ...
Near PT test card/illus of the ocular adnexa 5 1/2" X 8"....
Medicine Products: